Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy
Introduction Cancer treatment underwent significant changes in the last few years with the introduction of novel treatments targeting the immune system. Objectives The objective of this review is to discuss novel anticancer drugs including kinase inhibitors, biologics and cellular therapy with CAR-T...
Saved in:
Published in | Inflammation research Vol. 74; no. 1; p. 41 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.12.2025
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Introduction
Cancer treatment underwent significant changes in the last few years with the introduction of novel treatments targeting the immune system.
Objectives
The objective of this review is to discuss novel anticancer drugs including kinase inhibitors, biologics and cellular therapy with CAR-T cells.
Methods
Most recent research articles were extracted from PubMed using keywords such as “kinases inhibitors”, “CAR-T cell therapy”.
Results and discussion
The number of kinase inhibitors is significantly increasing due to their demonstrated effectiveness in combination with biologics. CAR-T represented a major breakthrough in the field. Also, it focused on their mechanisms of action and the rational of their use either alone or in combination in relation to their modes of action. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
ISSN: | 1023-3830 1420-908X 1420-908X |
DOI: | 10.1007/s00011-025-02008-5 |